ReviewA meta-analysis of hippocampal atrophy rates in Alzheimer's disease
Introduction
Alzheimer's disease (AD) is a large and growing problem with increasing financial and social burdens to the individual, carers and society. AD affects over 5% of the population over 60 years (Dawbarn and Allen, 2001) and its prevalence doubles every 5–10 years above that age (Small et al., 1997). A definitive diagnosis of AD can only be given following pathologic examination of the brain, usually at post-mortem. The disease is pathologically characterised by the presence of microscopic extracellular neuritic plaques and intracellular neurofibrillary tangles. AD tangle pathology progresses from medial temporal lobe structures such as the entorhinal cortex and hippocampus, to encompass the whole cortex, whereas plaque pathology is largely cortical and increases with disease severity (Braak et al., 1993). One of the results of this pathology is cerebral atrophy which can be visualised using structural MRI (Scheltens et al., 2002). The atrophy can be seen even at a single time-point, as brain structures in Alzheimer's subjects are smaller on average compared with controls. In addition, loss of tissue volume over time can also be detected in large regions such as the whole brain (Jack et al., 2004) and in smaller temporal areas such as the hippocampus (Jack et al., 2004) and entorhinal cortex (Du et al., 2004). This has led to a number of studies that have suggested that hippocampal atrophy rates may be useful both diagnostically, and to track disease progression.
Many studies assessing longitudinal hippocampal change have been reported in the literature (Fox et al., 1996, Jack et al., 2004, Kaye et al., 2005). Different methods have been used to generate these rates of atrophy including automated (Wang et al., 2003, Du et al., 2004) and manual techniques (Jack et al., 2004, Barnes et al., 2005). In addition, different populations of patients have also been included. To the best of our knowledge, no statistical review of the hippocampal atrophy rate literature has been conducted to date. Such a review is required to assess heterogeneity of reported studies, to better understand how age and disease severity affect the calculated atrophy rates, and to pool the results from these studies to more accurately estimate the rate of atrophy of the hippocampus in AD and matched control groups. This type of analysis may also be useful in identifying outlier results where the methodology employed may deserve critical review. In addition measuring the inter-site variance in hippocampal atrophy rates may be useful for anyone planning a multi-site trial, as it may define the level of consistency to expect in the imaging measures across sites.
The objective of this study is to perform a meta-analysis of hippocampal atrophy rates in patients with AD and matched controls from studies reported in the peer-reviewed literature.
Section snippets
Methods
The following protocol was employed in the study.
Results
Our Medline search strategy identified 535 papers, 19 of which satisfied our inclusion criteria. Eleven of these 19 papers were excluded, because: six presented overlapping data with the primary report already included (Jack et al., 1998, Jack et al., 2000, Mori et al., 2002, Silbert et al., 2003, Barnes et al., 2004, Barnes et al., 2007a), three did not report annualised atrophy rate (Laakso et al., 2000, Krishnan et al., 2003, Hampel et al., 2005) and two included patients with Vascular
Discussion
This study aimed to estimate the mean rate of hippocampal atrophy across a number of published studies. In addition, this study aimed to formally assess some aspects of the heterogeneity in these studies. Meta-analysis plays an important role in summarising results from studies owing to between-study heterogeneity. Effects of confounders such as disease severity or age may be lessened by pooling results from all studies, making the results more applicable to the wider population.
Hippocampal
Conclusions
The overall hippocampal atrophy rate is 1.4% in normal controls with the range of the quoted mean age being 69–83 years. In AD subjects the overall atrophy rate is 4.6%.
Disclosures
None of the authors have any disclosures to make.
Acknowledgements
This work was undertaken at UCLH/UCL who received a proportion of funding from the Department of Health's NIHR Biomedical Research Centres funding scheme. The Dementia Research Centre is an Alzheimer's Research Trust Co-ordinating Centre. JB is funded by the Alzheimer's Research Trust (UK). NF is funded by the Medical Research Council (UK). PT is supported by the National Institute on Aging (grant AG016570).
The authors would like to thank all those who contributed to this paper including
References (36)
- et al.
Atrophy rates of the cingulate gyrus and hippocampus in AD and FTLD
Neurobiol. Aging
(2007) - et al.
Automatic calculation of hippocampal atrophy rates using a hippocampal template and the boundary shift integral
Neurobiol. Aging
(2007) - et al.
Differentiating AD from aging using semiautomated measurement of hippocampal atrophy rates
Neuroimage
(2004) - et al.
Comparison of methods for measuring longitudinal brain change in cognitive impairment and dementia
Neurobiol. Aging
(2003) - et al.
Hippocampus in Alzheimer's disease: a 3-year follow-up MRI study
Biol. Psychiatry
(2000) - et al.
Tracking atrophy progression in familial Alzheimer's disease: a serial MRI study
Lancet Neurol.
(2006) - et al.
Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion
Lancet Neurol.
(2002) - et al.
Mapping hippocampal and ventricular change in Alzheimer disease
Neuroimage
(2004) - et al.
Changes in hippocampal volume and shape across time distinguish dementia of the Alzheimer type from healthy aging
Neuroimage
(2003) - et al.
Does Alzheimer's disease affect hippocampal asymmetry? Evidence from a cross-sectional and longitudinal volumetric MRI study
Dement. Geriatr. Cogn. Disord.
(2005)